Clinical Trials Logo

Sphingolipidoses clinical trials

View clinical trials related to Sphingolipidoses.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT02416661 Completed - Gaucher Disease Clinical Trials

Lyso-Gb1 as a Long-term Prognostic Biomarker in Gaucher Disease

LYSO-PROOF
Start date: August 27, 2018
Phase:
Study type: Observational

International, multicenter, epidemiological study to demonstrate the correlation and predictive value of lyso-Gb1 concentration with the clinical severity of naïve, initially non-ERT/SRT Gaucher disease type 1 and during the study ERT/SRT-newly started Gaucher type 1 patients and to correlate lyso-Gb1 concentration with the clinical improvement of ERT or SRT treated Gaucher type 1 and the clinical course of non-treated patients based on GD-DS3

NCT ID: NCT01043640 Completed - Hunter Syndrome Clinical Trials

Allogeneic Bone Marrow Transplant for Inherited Metabolic Disorders

Start date: December 2009
Phase: Phase 2
Study type: Interventional

Rationale: Chemotherapy administration before a donor stem cell transplant is necessary to stop the patient's immune system from rejecting the donor's stem cells. When healthy stem cells from a donor are infused into the patient, the donor white blood cells can provide the missing enzyme that causes the metabolic disease. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving a monoclonal antibody, alemtuzumab, before transplant and cyclosporine and mycophenolate mofetil before and after transplant may stop this from happening. This may be an effective treatment for inherited metabolic disorders. Purpose: The design of this study is to achieve donor cell engraftment in patients with standard-risk inherited metabolic diseases with limited peri-transplant morbidity and mortality. This will be achieved through the administration of the chemotherapy regimen described. The intention is to follow transplanted patient for years after transplant monitoring them for complications of their disease and assisting families with a multifaceted interdisciplinary approach.